Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Diabetologia
Published in: Diabetologia 6/2006

01-06-2006 | Article

The equivocal metabolic response to endotoxaemia in type 2 diabetic and obese ZDF rats

Authors: L. Belabed, G. Senon, M.-C. Blanc, A. Paillard, L. Cynober, S. Darquy

Published in: Diabetologia | Issue 6/2006

Login to get access

Abstract

Aims/hypothesis

The metabolic and endocrine disturbances associated with obesity and type 2 diabetes may impair the normal metabolic response to injury. Our objective was to investigate amino acid metabolism in endotoxaemic type 2 diabetic obese rats.

Materials and methods

A metabolic study was performed over 4 days using male Zucker diabetic fatty (ZDF) rats (fa/fa) and lean littermates (fa/+) divided into three groups: ad libitum-fed groups which underwent no treatment, lipopolysaccharide (LPS)-treated groups receiving E. coli LPS by i.p. injection, and pair-fed groups to the respective LPS groups. We evaluated the effect of endotoxaemia on body weight, food intake and tissue weights. Nitrogen loss and muscular proteolysis were measured daily by determination of urinary 3-methylhistidine (3-MH) excretion. Plasma, intestine and muscle amino acid levels were measured.

Results

The data showed that ad libitum-fed ZDF rats had lower plasma arginine and glutamine levels than ad libitum-fed control rats. Compared with control rats, the LPS-treated ZDF rats presented lower thymic involution, a lower 3-MH:creatinine ratio and higher cumulative nitrogen balance.

Conclusions/interpretation

Against our working hypothesis, ZDF rats did not show an impaired metabolic response, and even appeared to be less sensitive to the stress.
Literature
1.
2.
Dhatariya K, Sreekumaran Nair K (2004) Diabetes mellitus. In: Cynober L (ed.) Metabolic and therapeutics aspects of amino acids in clinical nutrition. CRC, Boca Raton, Florida, pp 355–373
3.
4.
Biolo G, Toigo G, Ciocchi B et al (1997) Metabolic response to injury and sepsis: changes in protein metabolism. Nutrition 13:52S–57SPubMedCrossRef
5.
Van Den Berghe G, Wouters P, Weekers F et al (2001) Intensive insulin therapy in the critically ill patients. N Engl J Med 345:1359–1367PubMedCrossRef
6.
Chiolero RL, Tappy L, Berger MM (2003) Nutritional support of obese critically ill patients. Nestle Nutrition Workshop Series. Clinical and Performance Programme 187–200
7.
De Bandt JP (2004) Insulin and the regulation of amino acid catabolism and protein turnover. In: Cynober L (ed.) Metabolic and therapeutics aspects of amino acids in clinical nutrition. CRC, Boca Raton, Florida, pp 355–373
8.
Peterson RG, Shaw WN, Neel M-A et al (1990) Zucker diabetic fatty rat as a model for non-insulin-dependent diabetes mellitus. ILAR News 32:16–19
9.
Unger RH (1997) How obesity causes diabetes in Zucker diabetic fatty rats. Trends Endocrinol Metab 8:276–282PubMedCrossRef
10.
Pernet P, Coudray-Lucas C, Schneid C, Jardel A, Cynober L (2004) Dose dependency of the effect of ornithine alpha-ketoglutarate on tissue glutamine concentrations and hypercatabolic response in endotoxaemic rats. Br J Nutr 92:627–634PubMedCrossRef
11.
Loi C, Osowska S, Neveux N, Darquy S, Cynober L, Moinard C (2005) Effects of an immune-enhancing diet in endotoxemic rats. Nutrition 21:255–263PubMedCrossRef
12.
Schlegel L, Coudray-Lucas C, Barbut F, Le Boucher J, Pernet P, Cynober L (1999) Bacterial dissemination, rather than translocation, mediates hypermetabolic response in endotoxemic rats. Crit Care Med 27:1511–1516PubMedCrossRef
13.
Wijekoon EP, Skinner C, Brosnan ME, Brosnan JT (2004) Amino acid metabolism in the Zucker diabetic fatty rat: effects of insulin resistance and of type 2 diabetes. Can J Physiol Pharmacol 82:506–514PubMedCrossRef
14.
Young VR, Munro HN (1978) Ntau-methylhistidine (3-methylhistidine) and muscle protein turnover: an overview. Fed Proc 37:2291–2300PubMed
15.
Blanc MC, Neveux N, Laromiguiere M, Berard MP, Cynober L (2000) Evaluation of a newly available biochemical analyzer: the Olympus AU 600. Clin Chem Lab Med 38:465–475PubMedCrossRef
16.
Grimble GK, West MF, Acuti AB et al (1988) Assessment of an automated chemiluminescence nitrogen analyzer for routine use in clinical nutrition. JPEN J Parenter Enteral Nutr 12:100–106PubMedCrossRef
17.
Green LC, Wagner DA, Glogowski J, Skipper PL, Wishnok JS, Tannenbaum SR (1982) Analysis of nitrate, nitrite, and [15N]nitrate in biological fluids. Anal Biochem 126:131–138PubMedCrossRef
18.
Unger RH, Orci L (2001) Diseases of liporegulation: new perspective on obesity and related disorders. FASEB J 15:312–321PubMedCrossRef
19.
Blanc MC, Moinard C, Béziel A, Darquy S, Cynober L, De Bandt JP (2004) Arginine and glutamine availability and macrophage functions in the obese insulin-resistant Zucker rat. J Cell Physiol 202:153–159CrossRef
20.
Long K, Tayek JA (1999) Are gluconeogenic amino acids reduced in obese and non-obese type 2 diabetic patients (DM-2) compared to weight similar normal volunteers? Diabetes 48:A460–A461CrossRef
21.
Morris SM J (2000) Regulation of arginine availability and its impact on NO synthesis. In: Ignarro JL (ed) Nitric oxide: biology and pathobiology. Academic, San Diego, California, pp 187–197
22.
Fu WJ, Haynes TE, Kohli R et al (2005) Dietary l-arginine supplementation reduces fat mass in Zucker diabetic fatty rats. J Nutr 135:714–721PubMed
23.
Stumvoll M, Perriello G, Nurjhan N et al (1996) Glutamine and alanine metabolism in NIDDM. Diabetes 45:863–868PubMedCrossRef
24.
Brosnan JT, Man KC, Hall DE, Colbourne SA, Brosnan ME (1983) Interorgan metabolism of amino acids in streptozotocin-diabetic ketoacidotic rat. Am J Physiol 244:E151–E158PubMed
25.
Rodriguez T, Alvarez B, Busquets S, Carbo N, Lopez-Soriano FJ, Argiles JM (1997) The increased skeletal muscle protein turnover of the streptozotocin diabetic rat is associated with high concentrations of branched-chain amino acids. Biochem Mol Med 61:87–94PubMedCrossRef
26.
Nair KS, Short KR (2005) Hormonal and signaling role of branched-chain amino acids. J Nutr 135:1547S–1552SPubMed
27.
Manco M, Mingrone G (2005) Effects of weight loss and calorie restriction on carbohydrate metabolism. Curr Opin Clin Nutr Metab Care 8:431–439PubMedCrossRef
28.
Marchesini G, Bianchi GP, Vilstrup H, Capelli M, Zoli M, Pisi E (1991) Elimination of infused branched-chain amino-acids from plasma of patients with non-obese type 2 diabetes mellitus. Clin Nutr 10:105–113PubMedCrossRef
29.
Freyse EJ, Fischer U, Knospe S, Ford GC, Nair KS (2006) Differences in protein and energy metabolism following portal versus systemic administration of insulin in diabetic dogs. Diabetologia 49:543–551PubMedCrossRef
30.
Lasnier E, Coudray-Lucas C, Le Boucher J, Jardel A, Cynober L (1997) Ornithine a-ketoglutarate counteracts thymus involution and glutamine depletion in endotoxemic rats. Clin Nutr 77:197–200
31.
Breuille D, Voisin L, Contrepois M, Arnal M, Rose F, Obled C (1999) A sustained rat model for studying the long-lasting catabolic state of sepsis. Infect Immun 67:1079–1085PubMed
32.
Cooney RN, Kimball SR, Vary TC (1997) Regulation of skeletal muscle protein turnover during sepsis: mechanisms and mediators. Shock 7:1–16PubMedCrossRef
33.
34.
Abumrad N, Barbul A (2003) The use of arginine in clinical practice. In: Cynober L (ed.) Metabolic and therapeutics aspects of amino acids in clinical nutrition. CRC, Boca Raton, Florida, pp 355–373
35.
Long CL, Birkhahn RH, Geiger JW, Betts JE, Schiller WR, Blakemore WS (1981) Urinary excretion of 3-methylhistidine: an assessment of muscle protein catabolism in adult normal subjects and during malnutrition, sepsis, and skeletal trauma. Metabolism 30:765–776PubMedCrossRef
36.
Minet-Quinard R, Moinard C, Walrand S et al (2000) Induction of a catabolic state in rats by dexamethasone: dose or time dependency? JPEN J Parenter Enteral Nutr 24:30–36PubMedCrossRef
37.
Mills CD (2001) Macrophage arginine metabolism to ornithine/urea or nitric oxide/citrulline: a life or death issue. Crit Rev Immunol 21:399–426PubMed
38.
Austgen TR, Chakrabarti R, Chen MK, Souba WW (1992) Adaptive regulation in skeletal muscle glutamine metabolism in endotoxin-treated rats. J Trauma 32:600–606PubMedCrossRef
39.
Parry-Billings M, Leighton B, Dimitriadis G, de Vasconcelos PR, Newsholme EA (1989) Skeletal muscle glutamine metabolism during sepsis in the rat. Int J Biochem 21:419–423PubMedCrossRef
40.
Darmaun D (1999) Role of nutrients in the regulation of in vivo protein metabolism in humans. Acta Paediatr Suppl 88:92–94PubMedCrossRef
41.
Jeevanandam M, Ramias L, Schiller WR (1991) Altered plasma free amino acid levels in obese traumatized man. Metabolism 40:385–390PubMedCrossRef
42.
Jeevanandam M, Young DH, Schiller WR (1991) Obesity and the metabolic response to severe multiple trauma in man. J Clin Invest 87:262–269PubMedCrossRef
43.
Forbes GB, Drenick EJ (1979) Loss of body nitrogen on fasting. Am J Clin Nutr 32:1570–1574PubMed
44.
Leiter LA, Marliss EB (1982) Survival during fasting may depend on fat as well as protein stores. JAMA 248:2306–2307PubMedCrossRef
45.
Elia M, Stubbs RJ, Henry CJ (1999) Differences in fat, carbohydrate, and protein metabolism between lean and obese subjects undergoing total starvation. Obes Res 7:597–604PubMed
46.
Tessari P, Nissen SL, Miles JM, Haymond MW (1986) Inverse relationship of leucine flux and oxidation to free fatty acid availability in vivo. J Clin Invest 77:575–581PubMedCrossRef
47.
Beaufrere B, Chassard D, Broussole C, Riou JP, Beylot M (1992) Effects of d-beta-hydroxy-butyrate, long and medium chain triglycerides on leucine metabolism in man. Am J Physiol 262:E268–E274PubMed
Metadata
Title
The equivocal metabolic response to endotoxaemia in type 2 diabetic and obese ZDF rats
Authors
L. Belabed
G. Senon
M.-C. Blanc
A. Paillard
L. Cynober
S. Darquy
Publication date
01-06-2006
Publisher
Springer-Verlag
Published in
Diabetologia / Issue 6/2006
Print ISSN: 0012-186X
Electronic ISSN: 1432-0428
DOI
https://doi.org/10.1007/s00125-006-0233-4

Other articles of this Issue 6/2006

Diabetologia 6/2006 Go to the issue

Short Communication

Increased prevalence of Down’s syndrome in individuals with type 1 diabetes in Denmark: a nationwide population-based study

Article

A new model of insulin-deficient diabetes: male NOD mice with a single copy of Ins1 and no Ins2

Review

Proinsulin in development: new roles for an ancient prohormone

Article

Comparison of the pharmacokinetics and pharmacodynamics of biphasic insulin aspart and insulin glargine in people with type 2 diabetes

Commentary

Digami too?

Article

Differential effects of monounsaturated, polyunsaturated and saturated fat ingestion on glucose-stimulated insulin secretion, sensitivity and clearance in overweight and obese, non-diabetic humans
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits